CNO (NYSE: CNO) insider files to sell 9,000 common shares

Rhea-AI Filing Summary

CNO Financial Group insider Yvonne K. Franzese has filed a Form 144 indicating an intention to sell 9,000 shares of CNO common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $388,556.70 and an approximate sale date of February 17, 2026 on the NYSE.

The notice shows these 9,000 shares were acquired as performance shares from the issuer on February 10, 2026. It also discloses a prior sale of 3,000 common shares on November 24, 2025 for gross proceeds of $123,000. Shares outstanding were 95,353,512 as of the filing, which is a baseline figure, not the amount being sold.

By signing the notice, the seller represents that they do not know of any material adverse, nonpublic information about CNO’s operations, and acknowledges the additional representation required if relying on a Rule 10b5-1 trading plan.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9000	388556.70	95353512	02/17/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/10/2026	Performance Shares	ISSUER			9000	02/10/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
YVONNE K FRANZESE 11299 Illinois Street Carmel IN 46032	Common	11/24/2025	3000	123000.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for CNO by Yvonne K. Franzese disclose?

The filing discloses an intended sale of 9,000 CNO common shares. These shares are to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $388,556.70 and an approximate sale date of February 17, 2026 on the NYSE.

How many CNO shares does Yvonne K. Franzese plan to sell and at what value?

Yvonne K. Franzese plans to sell 9,000 CNO common shares. The Form 144 lists an aggregate market value of $388,556.70 for this planned transaction, based on the market price at the time the notice was prepared for NYSE trading.

When and how were the CNO shares in this Form 144 acquired?

The 9,000 CNO shares were acquired on February 10, 2026 as performance shares from the issuer. The filing shows the nature of the acquisition transaction as “Performance Shares,” with the same February 10, 2026 date listed for both acquisition and payment.

What prior CNO share sales by Yvonne K. Franzese are disclosed in the Form 144?

The notice reports a prior sale of 3,000 CNO common shares on November 24, 2025. That earlier transaction generated gross proceeds of $123,000. This disclosure covers securities of the same issuer sold during the past three months by the same seller.

How many CNO shares were outstanding relative to this planned 9,000-share sale?

The Form 144 states that 95,353,512 CNO common shares were outstanding. This figure represents the company’s total shares outstanding referenced in the filing, providing context relative to the planned 9,000-share sale by the insider.

What representations does the seller make in CNO’s Form 144 filing?

By signing, the seller represents that they do not know any material adverse information about CNO’s current or prospective operations that has not been publicly disclosed. If relying on a Rule 10b5-1 plan, that representation is also made as of the plan’s adoption date.